Humacyte Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
HUMA$0.59+29.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(88,559) | $(59,675) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 2,530 | 3,026 |
| Stock-based compensation expense | 2,891 | 3,650 |
| Change in fair value of Contingent Earnout Liability | 30,164 | 10,564 |
| Non-cash interest expense | 3,544 | 737 |
| Change in fair value of derivative liabilities | 328 | 99 |
| Loss on extinguishment of debt | — | 2,421 |
| Loss on disposal of property and equipment | — | 9 |
| Amortization expense | 1,040 | 1,030 |
| Non-cash operating lease costs | 26 | 24 |
| Amortization of SVB debt discount | — | 482 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 31 |
| Prepaid expenses and other current assets | 283 | (3,660) |
| Accounts payable | (638) | 766 |
| Accrued expenses | (221) | (724) |
| Operating lease obligation | (26) | (24) |
| Net cash used in operating activities | (48,638) | (41,244) |
| Cash flows from investing activities | ||
| Proceeds from maturity of short-term investments (certificates of deposit) | — | 2,107 |
| Purchase of property and equipment | (575) | (1,637) |
| Net cash (used in) provided by investing activities | (575) | 470 |
| Cash flows from financing activities | ||
| Proceeds from issuance of stock in public offering, net of underwriting fees | 43,396 | — |
| Payments of costs related to public offering | (350) | — |
| Proceeds from revenue interest purchase agreement, net of issuance costs | 20,000 | 39,377 |
| Payments of transaction costs related to revenue interest purchase agreement | (500) | (1,164) |
| Proceeds from the exercise of stock options | 789 | 214 |
| Proceeds from JDRF Agreement | 240 | 80 |
| Payments of finance lease principal | (1,247) | (1,091) |
| Principal payments on SVB loan | — | (31,500) |
| Payments for debt prepayment and extinguishment costs | — | (310) |
| Net cash provided by financing activities | 62,328 | 5,606 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,115 | (35,168) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 80,801 | 149,772 |
| Cash, cash equivalents and restricted cash at the end of the period | $93,916 | $114,604 |
| Supplemental disclosure: | ||
| Cash paid for interest on SVB loan | $— | $1,613 |
| Supplemental disclosure of noncash activities: | ||
| Debt discount from embedded contingent derivative liability | $1,552 | $2,354 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.